RATIONALE: The noradrenergic system might be a critical mediator of psychostimulants and opiates hedonic value. OBJECTIVES: The objective of this study is to evaluate the involvement of alpha1-adrenoceptors (alpha1-ARs) in nicotine incentive learning. MATERIALS AND METHODS: Rats, subjected to an unbiased conditioned place preference (CPP) procedure, received eight 30-min alternating nicotine (0.06 mg/kg) and saline pairings with distinct floor textures. The alpha1-AR antagonist, prazosin (0.125, 0.25, 0.5, or 1 mg/kg), was administered 30 min before nicotine pairings (acquisition) or one of the two 20-min test sessions conducted 24 h and 3 weeks after conditioning (expression). RESULTS: Pre-pairing injections of prazosin (0.5-1 mg/kg) prevented the acquisition of nicotine-CPP. On pre-test administration, prazosin (0.5 mg/kg) abolished the short-term expression of nicotine-CPP; whereas, none of the tested doses impaired its long-term expression. During a drug-free 3-week test session, nicotine-CPP was also weakened in rats given prazosin (0.5 mg/kg) before the 24-h test, while nicotine-CPP was reduced neither in animals given prazosin immediately after the first test session nor in those not subjected to the 24-h test. CONCLUSIONS: The activation of alpha1-ARs is one of the mechanisms that code for the incentive motivational value of nicotine. It participates also in the short-term, but not the long-term, control of behavior by nicotine-paired stimuli. The latter effect does not result from disruption by prazosin of either memory for the nicotine-cue association or reconsolidation processes at recall. Thus, differences exist in the neurobiological mechanisms that contribute to the incentive motivational value of nicotine and the short- and long-term "memory" of the incentive salience acquired by nicotine-paired cues.
RATIONALE: The noradrenergic system might be a critical mediator of psychostimulants and opiates hedonic value. OBJECTIVES: The objective of this study is to evaluate the involvement of alpha1-adrenoceptors (alpha1-ARs) in nicotine incentive learning. MATERIALS AND METHODS:Rats, subjected to an unbiased conditioned place preference (CPP) procedure, received eight 30-min alternating nicotine (0.06 mg/kg) and saline pairings with distinct floor textures. The alpha1-AR antagonist, prazosin (0.125, 0.25, 0.5, or 1 mg/kg), was administered 30 min before nicotine pairings (acquisition) or one of the two 20-min test sessions conducted 24 h and 3 weeks after conditioning (expression). RESULTS: Pre-pairing injections of prazosin (0.5-1 mg/kg) prevented the acquisition of nicotine-CPP. On pre-test administration, prazosin (0.5 mg/kg) abolished the short-term expression of nicotine-CPP; whereas, none of the tested doses impaired its long-term expression. During a drug-free 3-week test session, nicotine-CPP was also weakened in rats given prazosin (0.5 mg/kg) before the 24-h test, while nicotine-CPP was reduced neither in animals given prazosin immediately after the first test session nor in those not subjected to the 24-h test. CONCLUSIONS: The activation of alpha1-ARs is one of the mechanisms that code for the incentive motivational value of nicotine. It participates also in the short-term, but not the long-term, control of behavior by nicotine-paired stimuli. The latter effect does not result from disruption by prazosin of either memory for the nicotine-cue association or reconsolidation processes at recall. Thus, differences exist in the neurobiological mechanisms that contribute to the incentive motivational value of nicotine and the short- and long-term "memory" of the incentive salience acquired by nicotine-paired cues.
Authors: Jesse R Schank; Rossella Ventura; Stefano Puglisi-Allegra; Antonio Alcaro; Charlene D Cole; L Cameron Liles; Philip Seeman; David Weinshenker Journal: Neuropsychopharmacology Date: 2005-12-14 Impact factor: 7.853
Authors: Patricia Di Ciano; Daniel F Manvich; Abhiram Pushparaj; Andrew Gappasov; Ellen J Hess; David Weinshenker; Bernard Le Foll Journal: Psychopharmacology (Berl) Date: 2017-10-30 Impact factor: 4.530
Authors: Bernard Le Foll; Mihail Guranda; Alan A Wilson; Sylvain Houle; Pablo M Rusjan; Victoria C Wing; Laurie Zawertailo; Usoa Busto; Peter Selby; Arthur L Brody; Tony P George; Isabelle Boileau Journal: Neuropsychopharmacology Date: 2013-08-19 Impact factor: 7.853
Authors: Sherry A McKee; Marc N Potenza; Hedy Kober; Mehmet Sofuoglu; Amy F T Arnsten; Marina R Picciotto; Andrea H Weinberger; Rebecca Ashare; Rajita Sinha Journal: J Psychopharmacol Date: 2014-12-16 Impact factor: 4.153
Authors: Terril L Verplaetse; Andrea H Weinberger; Philip H Smith; Kelly P Cosgrove; Yann S Mineur; Marina R Picciotto; Carolyn M Mazure; Sherry A McKee Journal: Nicotine Tob Res Date: 2015-03-11 Impact factor: 4.244
Authors: Terril L Verplaetse; Andrea H Weinberger; Rebecca L Ashare; Brian P Pittman; Julia M Shi; Jeanette M Tetrault; Meaghan Lavery; Sherry A McKee Journal: J Psychopharmacol Date: 2018-04-25 Impact factor: 4.153
Authors: Kyrie-Anne E Reyes; Priya S Kudva; Benjamin Heckler; Angela E Gonzalez; Barbara A Sorg Journal: Neurosci Lett Date: 2020-11-06 Impact factor: 3.046